Mural Oncology (Mural Oncology) ROCE % : -52.87% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mural Oncology's annualized ROCE % for the quarter that ended in Mar. 2024 was -52.87%.

Mural Oncology ROCE % Historical Data

The historical data trend for Mural Oncology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology ROCE % Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-9,413.04

-148.15

Mural Oncology Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial				-	-66.95	-123.93	-169.28	-52.87

Mural Oncology ROCE % Calculation

Mural Oncology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-196.238	/	( ( (33.75 - 41.56)	+	(301.745 - 29.017) )	/ 2 )
	=	-196.238	/	( (-7.81	+	272.728)	/ 2 )
	=	-196.238	/	132.459
	=	-148.15 %

Mural Oncology's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-136.132	/	( ( (301.745 - 29.017)	+	(263.504 - 21.247) )	/ 2 )
	=	-136.132	/	( ( 272.728	+	242.257 )	/ 2 )
	=	-136.132	/	257.4925
	=	-52.87 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Mural Oncology (NAS:MURA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mural Oncology ROCE % Related Terms

Thank you for viewing the detailed overview of Mural Oncology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology (Mural Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin, IRL, D02 T380

Website

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.

Mural Oncology (Mural Oncology) Headlines

From GuruFocus

Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

By Marketwired • 04-24-2024